Financials

News Discussions Technicals Seasonals Bonds

BIIBD fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

‪20.47 B‬USD

—

15.07

0.76USD

1978

‪7.61 K‬

Christopher A. Viehbacher

About

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

‪‪20.47 B‬‬

Price to earning ratio (P/E)

15.07x

Price to sales ratio (P/S)

2.62x

Market Cap

Net income

Revenue

Price to earning ratio (P/E)

15.07x

Price to sales ratio (P/S)

2.62x

Valuation ratios

‪0.00‬

‪3.50‬

‪7.00‬

‪10.50‬

‪14.00‬

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

‪0.00‬

‪35.00‬

‪70.00‬

‪105.00‬

‪140.00‬

P/E

P/S

Growth and Profitability

Company’s recent performance and margins

Performance

‪10%‬

‪14%‬

‪18%‬

‪22%‬

‪26%‬

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

‪0.00‬

‪‪600.00 M‬‬

‪‪1.20 B‬‬

‪‪1.80 B‬‬

‪‪2.40 B‬‬

Revenue

Net income

Net margin %

Revenue to profit conversion

Revenue

COGS

Gross profit

Op expenses

Op income

Non-Op income/ expenses

Taxes & Other

Net income

‪0.00‬

‪‪600.00 M‬‬

‪‪1.20 B‬‬

‪‪1.80 B‬‬

‪‪2.40 B‬‬

Revenue

COGS

Gross profit

Expenses & adjustments

Net income

‪0.00‬

‪‪600.00 M‬‬

‪‪1.20 B‬‬

‪‪1.80 B‬‬

‪‪2.40 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business

Period: 2024

Innovative Therapies

By country

Period: 2024

United States

Europe

Germany

Asia

Other

Dividends

Dividend yield, history and sustainability

BIIBD does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

‪‪−2.50 B‬‬

‪0.00‬

‪‪2.50 B‬‬

‪‪5.00 B‬‬

‪‪7.50 B‬‬

Debt

Free cash flow

Cash & equivalents

Financial position analysis

Short term

Long term

‪0.00‬

‪‪6.00 B‬‬

‪‪12.00 B‬‬

‪‪18.00 B‬‬

‪‪24.00 B‬‬

Assets

Liabilities